1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D4 RECEPTOR SUBTYPE LIGANDS

Abstract: Disclosed are compounds of formula: (I) or pharmaceutically acceptable addition salts thereof, wherein: X, Y and Z are the same or different and represent optionally substituted carbon or nitrogen; R1 and R2 independently represent organic or inorganic substituents; R3 and R4 are variables independently representing inorganic or organic substituents; A represents C1-C4 alkylene; and R5, R6 and R7 independently represent hydrogen or C1-C6 alkyl, which compounds bind selectively with high affinity to the dopamine D4 receptor subtype and are therefore of use in treatment of various neuropsychological disorders.

Description: l -(2-NAPHTHYL) AND l-(2-AZANAPHTHYL)-4-(l-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D 4 RECEPTOR SUBTYPE LIGANDS 5 BACKGROUND OF THE INVENTION Field of the Invention This invention relates to certain 1- (2-naphthyl) and l-(2- azanaphthyl) -4- (1-phenylmethyl) piperazmes and pharmaceutical 0 compositions containing such compounds. It also relates to the use of such compounds in the treatment or prevention of psychotic disorders such as schizophrenia and other central nervous system diseases. 5 Description of the Related Art The therapeutic effect of conventional antipsychotics, known as neuroleptics , is generally believed to be exerted through blockade of dopamme receptors. However, neuroleptics are frequently responsible for undesirable extrapyramidal side 0 effects (EPS) and tardive dyskmesias, which are attributed to blockade of D2 receptors m the striatal region of the brain. The dopamme D4 receptor subtype has recently been identified (Nature, 347 : 146 (Sokoloff et al . , 1990)) . Its unique localization limbic brain areas and its differential 5 recognition of various antipsychotics suggest that the D4 receptor may play a major role the etiology of schizophrenia. Selective D4 antagonists are considered effective antipsychotics free from the neurological side effects displayed by conventional neuroleptics. Various 4-benzylpιperazmes have been described. See, for example, Arcn. Med. Res., 2J5: 435-440 (Terron et al . , 1994) and Toxicol. Appl . Pharmacol., 2 - 257-267 (Schmidt and Martin, 1965) . SUMMARY OF THE INVENTION This invention provides novel compounds which interact with dopamme subtypes. Accordingly, m a broad aspect, the invention provides compounds of Formula I : or pharmaceutically acceptable addition salts thereof, wherein: X, Y and Z are the same or different and represent CR C or nitrogen; R c represents hydrogen, halogen or alkyl; Ri and R 2 independently represent hydrogen, halogen, hydroxy, C 1 -C 6 alkyl, trifiuoromethyl, tπfluoromethoxy or S0 2 NH 2 , provided that, when Y and Z represent CH, and R, and R, are both hydrogen, R, and R 2 are not hydrogen simultaneously; or R λ and R 2 together represent a C -C 2 alkylene dioxy group or a C 1 -C alkylene oxy group; R 3 and R 4 are the same or different and represent hydrogen, halogen, C ! -C 6 alkyl, Cι-C 4 alkoxy, alkylthio, hydroxy, ammo, mono or dialkyl ammo where each alkyl is C -Cg alkyl, cyano or trifiuoromethyl; A represents C 1 -C alkylene; and R 5 , R 6 , and R 7 independently represent hydrogen or Cx-Cg alkyl. Dopamme D 4 receptors are concentrated in the limbic system (Science, 265 : 1034 (Taubes, 1994)) which controls cognition and emotion. Therefore, compounds that interact with these receptors are useful in the treatment of cognitive disorders. Such disorders include cognitive deficits which are a significant component of the negative symptoms (social withdrawal and unresponsiveness) of schizophrenia. Other disorders include those involving memory impairment or attention deficit disorders. Compounds of the present invention demonstrate high affinity and selectivity m binding to the D 4 receptor subtype. These compounds are therefore useful m treatment of a variety of neurospychological disorders, such as, for example, schizophrenia, psychotic depression and mania. Other dopamme- mediated diseases such as Park sonism and tardive dyskmesias can also be treated directly or indirectly by modulation of D 4 receptors . Thus, m another aspect, the invention provides methods for treatment and/or prevention of neuropsychochological or affective disorders including, for example, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, memory impairment, cognitive deficits, Parkmson-like motor disorders, e.g., Parkmsonism and dystonia, and motion disorders related to the use of neuroleptic agents. In addition, the compounds of the invention are useful treatment of depression, memory- impairment or Alzheimer's disease by modulation of D 4 receptors which selectively exist m limbic area known to control emotion and cognitive functions. Further, the compounds of the present invention are useful for the treatment of other disorders that respond to dopammergic blockade, e.g., substance abuse and obsessive compulsive disorder. These compounds are also useful m treating the extrapyramidal side effects associated with the use of conventional neuroleptic agentr In yet another aspect, the invention provides pharmaceutical compositions comprising compounds of Formula I . DETAILED DESCRIPTION OF THE INVENTION As mentioned above, the invention encompasses substituted 1- (2-naphthyl) and 1- (2-azanaphthyl) -4- (1- phenylmethyl) piperazmes of Formula I. Preferred compounds of Formula I are those where at least one of R x and R 2 is halogen, alkyl, trifiuoromethyl, trifluoromethoxy, or where R, and R 2 together represent 3 , 4-methylenedιoxy . Still other preferred compounds of Formula I are those where represents 4-alkylqumolmyl , 4,6- dialkylqumolinyl , 4 , 7-dialkylquinolinyl , 4,8- dialkylquinolinyl , 4-haloquinolinyl , or 4-alkyl-6- alkoxyquinolinyl . Preferably, only Z is R c . More preferred compounds of Formula I are those where at least one of R x and R 2 is chloro, fluoro, methyl, ethyl, butyl, isopropyl, n- propyl, trifiuoromethyl, trifluoromethoxy, or where R : and R 2 together represent 3 , 4-methylenedioxy . Particularly preferred compounds of Formula I are those where R 2 is hydrogen and R x is methyl or chloro. In addition, preferred compounds of Formula I are those where A is methylene or ethylene, and R c is hydrogen. Particularly preferred compounds of Formula I are those where represents qumol ιn-2 -yl , 5 , 6 , 7 , tetrahydroqumolm-2 -yl , qumoxalm- 2 -yl , or naphth- 2 -yl . The invention also encompasses compounds of formula I I II wherem: Rx, R 2 , R 3 , R 4 , R 5 , R δ / R c , and R 7 carry the same definitions as set forth above for Formula I . Preferred compounds of Formula II are those where at least one of R 1 and R 2 is halogen, alkyl, trifiuoromethyl, trifluoromethoxy, or where R x and R ^ together represent 3,4- methylenedioxy . Still other preferred compounds of Formula II are those where the both R 3 and R, are hydrogen, or the R„, R, and R 4 substitution on the qumolme ring provides a 4- alkylqumolmyl , 4 , 6-dιalkylqumolmyl , 4 , 7-dιalkylqumolmyl , 4 , 8-dιalkylqumoimyl , 4 -haloqumoimyl , or 4-alkyl-6- alkoxyqumolmyl compound. More preferred compounds of Formula II are those where A is methylene and at least one of R x and R 2 is chloro, fluoro, methyl, ethyl, butyl, isopropyl, n-propyl, trifluorometnyl , trifluoromethoxy, or wnere R_ and R ^ togetner represent 3 , 4 -methylenedioxy . Particularly preferred compounds of Formula II are those where R 3 and R 4 are hydrogen, A is methylene, R 2 is hydrogen and R λ is methyl or chloro. Particularly preferred compounds of Formula II are quinolm-2-yl derivatives where R 3 a2id R 4 are hydrogen. Other particularly preferred compounds of Formula II are 5,6,7,8- tetrahydroqumolm-2-yl derivatives where R 3 and R 4 are hydrogen . Also encompassed within the invention are compounds of Formula III: III wherem: Rx, R 2 R 3 , R 4 , R 5 , R 6 , and R 7 carry the same definitions as set forth above for Formula I. Preferred compounds of Formula III are those where at least one of R : and R 2 is halogen, alkyl, trifiuoromethyl, trifluoromethoxy, or where R, and R 2 together represent 3,4- methylenedioxy . More preferred compounds of Formula III are those where A is methylene and at least one of R, and R ^ s chloro, fluoro, methyl, ethyl, butyl, isopropyl, n-propyl, trifiuoromethyl, trifluoromethoxy, or where R, and R 2 together represent 3 , 4-methylenedιoxy . Particularly preferred compounds of Formula III are those where R 3 and R 4 are hydrogen, A is methylene, R 2 is hydrogen and R x is methyl or chloro. Particularly preferred compounds of Formula III are qumoxalm-2 -yl derivatives where R, and R , are hydrogen. The invention further provides compounds of formula IV: IV wherem: Rx, R 2 , R 3 , R 4 , R 5 , Rg, and R 7 carry the same definitions as set forth above for Formula I . Preferred compounds of Formula IV are those where at least one of R, and R 2 is halogen, alkyl, trifiuoromethyl, trifluoromethoxy, or where R : and R. together represent 3,4- methylenedioxy . More preferred compounds ϊrmuia IV those where A is methylene and at least one of R : and R 2 is chloro, fluoro, methyl, ethyl, butyl, isopropyl, n-propyl, trifluorometnyl , trifluoromethoxy , or where R, and R 2 together represent 3 , 4-methylenedιoxy . Particularly preferred compounds of Formula IV are those where R_ and R 4 are hydrogen, A is methylene, R 2 is hydrogen and R λ is methyl or chloro. The invention also encompasses compounds of formula V: wherem: Rx, R 2 , R 3 , R , R 5 , Rg, R C and R 7 carry the same definitions as set forth above for Formula I . Preferred compounds of Formula V are those where R„ is hydrogen; and at least one of R, and R 2 is halogen, alkyl, trifiuoromethyl, trifluoromethoxy, or where R : and R 2 together represent 3 , 4 -methylenedioxy . More preferred compounds of Formula V are those where R„ is hydrogen, A is methylene and at least one of R, and R 2 is chloro, fluoro, methyl, ethyl, butyl, isopropyl, n-propyl, trifiuoromethyl, trifluoromethoxy, or where R : and R, together represent 3 , 4 -methylenedioxy . Particularly preferred compounds of Formula V are those where R, and R 4 are hydrogen, A is methylene, R 2 is hydrogen and R ι is methyl or chloro. The particularly preferred compounds of Formula V are naphth-2-yl derivatives where R 3 and R_ are nydrogen. Particularly preferred compounds of Formulae I-V are those where R 5 , R 6 , and R. are hydrogen. The invention further provides intermediates useful m the preparation of compounds of Formula I. Such intermediates include those of Formula VIII. where X, Y, Z, R, , R 4 , and R 6 and R- are as defined above for Formula I . In certain situations, the compounds of this invention I may contain one or more asymmetric carbon atoms, so that the compounds can exist m different stereoisomer c forms These compounds can be, for example, racemates or optically active forms. In these situations, the single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization m the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column. Representative compounds of tne present invention, which are encompassed by Formula I, include, out are not limited to the compounds m Table I and their pharmaceutically acceptable acid addition salts. In addition, if the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basify g a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds . Non-toxic pharmaceutical salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfmic, formic, toluenesulfonic , methanesulfonic, nitric, benzoic, citric, tartaπc, maleic, hydroiodic, alkanoic such as acetic, HOOC- (CH 2 )n-ACOOH where n is 0-4, and the like. Those skilled m the art will recognize a wide variety of non-toxic pharmaceutically acceptable addition salts. The present invention also encompasses the acylated prodrugs of the compounds of Formula I. Those skilled m the art will recognize various synthetic methodologies which may be employed to prepare non-toxic pharmaceutically acceptable addition salts and acylated prodrugs of the compounds encompassed by Formula I . By the use herein of dashed lines in the structural representations of the compounds of the invention is meant that the carbon atoms connected by the dashed line are linked either by single or double carbon-carbon bonds. The use herein of the following structure where A represents C 1 -C 4 alkylene and R 5 is hydrogen or lower alkyl ("the AR 5 group"), means alkylene groups having from 1-4 carbon atoms each of which carbon atoms is optionally substituted with a lower alkyl group. Examples of such a structure are methylene, ethylene, propylene, and butylene. A particularly preferred AR 5 group according to the invention is methylene, i.e., -CH 2 - . By alkyl or lower alkyl in the present invention is meant C j -Cg alkyl, i.e., straight or branched chain alkyl groups having 1-6 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec -butyl, ter -butyl, pentyl , 2- pentyl, isopentyl, neopentyl , hexyl , 2-hexyl, 3-hexyi, and 3- methylpentyl . By alkoxy or lower alkoxy m the present invention is meant C -C f alkoxy, l . e ., straight or branched chain alkoxy groups naving 1-6 carbon atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2 -pentyl, isopentoxy, neopentoxy, hexoxy, 2 -hexoxy, 3- hexoxy, and 3 -methylpentoxy . By cycloalkoxy the present invention is meant cycloalkylalkoxy groups having 3-7 carbon atoms where cycloalkyl is defined above. By Ci-C j alkylene dioxy group is meant a group of the formula : where n is 1 or 2. By C^C- j alkylene oxy group is meant a group of the formula : where n is 1, 2 or 3. By halogen in the present invention is meant fluorine, bromine, chlorine, and iodine. Representative compounds of the invention are shown below m Table 1. Table 1 Compound 1 Compound 2 Compound 3 Compound 4 Compound 7 The compounds of the invention are useful m the treatment of neuropsychological disorders; the pharmaceutical utility of compounds of this invention is indicated by the assays for dopamme receptor subtype affinity described below ±n the Examples. The interaction of the 1- (2-naphthyl) and l-(2- azanaphthyl) -4- (1-phenylmethyl) -piperazmes of the invention with dopamme receptor subtypes results m the pharmacological activities of these compounds. The compounds of general formula I may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, trasternal injection or infusion techniques. In addition, there is provided a pharmaceutical formulation comprising a compound of general formula I and a Larmaceutιcally acceptable carrier. One or more compounds of general formula I may be present association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients. The pharmaceutical compositions containing compounds of general formula I may be m a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient m admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or algmic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption m the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. Formulations for oral use may also be presented as hard gelatin capsules wherem the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherem the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil. Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose , methylcellulose, hydropropylmethylcellulose , sodium algmate, polyvinylpyrrolidone, gum tragacanth and gum acacia,* dispersing or wetting agents may be a naturally-occurring p osphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example neptadecaethyleneoxycetanoi , or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate , one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin. Oily suspensions may be formulated by suspending the active ingredients m a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or m a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also oe present. Pharmaceutical compositions of the invention may also be m the form of oil-m-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides , for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents . Syrups and elixirs may be formulated with sweetening agents, for example glycerol , propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be m the form of a sterile mjectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile mjectable preparation may also be sterile mjectable solution or suspension m a non-toxic parentally acceptable diluent or solvent, for example as a solution m 1 , 3 -butanediol . Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and lsotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglyceπdes . In addition, fatty acids such as oleic acid find use m the preparation of mjectables. The compounds of general formula I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-imtatmg excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. Compounds of general formula I may be administered parenterally m a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved m the vehicle. Dosage levels of the order of from aoout 0. lmg to about 140mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5mg to about 7g per patient per day) . The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about lmg to about 500mg of an active ingredient. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, genera" health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Representative illustrations of methods suitable for the preparation of compounds of the present invention are shown m the following Schemes. Those having skill m the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention. For example, in certain situations, protection of reactive moieties such as ammo groups, will be required. An azanaphthyl compound of Formula I may be prepared according to Scheme 1. Scheme 1 In Scheme 1, R 1( R 2 , R 3 , R , R 5 , Rg , R 7 , X, Y and Z are as defined above for Formula I . As shown, an azanaphthyl compound of general structure VI, having an appropriate leaving group L at the position indicated, is condensed with a piperazme compound of general structure VII to provide a 1 -azanaphthyl piperazme of general structure VIII. Compound VIII may then be condensed with a benzylic compound of general structure IX having an appropriate benzylic leaving group L 2 to provide a 1-azanaphthyl -4 - ( 1 - phenylmethyl) piperazme of Formula I. The leaving groups L and L 2 may be halides, sulfonate esters or the like. Those having skill m the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention. Alternatively, an azanaphthyl compound of the invention may be prepared according to Scheme 2. Scheme 2 x XI Δ In Scheme 2, R 1; R 2 , R 3 , R 4 , R 5 , R , R 7 , X, Y and Z are as defined above for Formula I . As shown, an azanaphthyl compound of general structure X, having an appropriate leaving group L at the position indicated, is condensed with a 1-subst tuted piperazme compound of general structure XI to provide a l-azanaphthyl-4- (1-phenylmethyl) piperazine of Formula I. The leaving group L may be a halide, sulfonate ester or the like. Those having skill m the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention. Naphthyl compounds of the invention may be prepared according to Scheme 3. Scheme 3 In Scheme 3, R x , R 2 , R 3 , R 4 , R 5 , Rg and R 7 carry the same definitions as set forth above for Formula I . As shown, an 2-naphthylpιperazme compound of general structure XII is condensed with a benzylic compound of general structure IX having an appropriate benzylic leaving group L 2 to provide a l-naphthyl-4- (1-phenylmethyl) piperazme of Formula I. The leaving group L 2 may be a halide, a sulfonate ester or the like. The starting materials are either commercially available or may be prepared using common synthetic methods described within the body of chemical literature. Those having skill m the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed hy the present inventions, as demonstrated by the following examples. In some cases, protection of certain reactive functionalities may be necessary to achieve some of the above transformations. In general, the need for such protecting groups will be apparent to those skilled in the art of organic synthesis as well as the conditions necessary to attach and remove such groups. The disclosures m this application of all articles and references, including patents, are incorporated herein by reference . The invention is illustrated further by the following examples which are not to be construed as limiting the invention m scope or spirit to the specific procedures described them. Example 1 1. 2 , 4-Dιchloroσumazol ne A solution of 25 g of benzoyleneurea and 12 mL of diethyl aniline m 200 πL of phosphorus oxychloride is refluxed for 4 days after which excess phosphorus oxychloride is removed on a rotovap and the remaining residue poured onto ice. The mixture is then extracted with ethyl acetate and the compmed organic extracts washed with water, 1 N NaOH solution, dried and concentrated. The residue is recrystalized from isopropanol to provide 11 g of the dichloroqumazol e as of f -white needles irn . p . 64 - 66 ° C ) . 2 -Chloroqumazolme A two-phase mixture of a solution of 2, 4 -dichloroqumazolme (5 g) m methylene chloride (100 mL) covered with 100 mL of saturated brine containing 9% NH 4 OH is treated with powdered zmc (5 g) and the resultant mixture is then refluxed for 4 h, cooled and filtered through celite. The organic layer is removed, diluted with ethyl acetate (100 ml) , washed with 1 N HC1 solution, dried and concentrated. 2 -Piperazmylσumazolme A solution of 2 -chloroqumazolme (5 g) m 20 mL of toluene is added dropwise to a refluxmg solution of piperazme (20 g) m 150 mL of toluene and the resultant solution refluxed for an additional 24 h. After cooling to 0 °C for 0.5 h, the solution is filtered and the filtrate extracted with 10 % acetic acid. The aqueous extracts are washed with ether, basified and extracted with toluene. The toluene layer is then washed with water, dried and concentrated. Finally, the material is placed under vacuum overnight (6.8 g, m.p. 188-121 °C) . 4. 2 - (4 - ( (4 -chlorophenyl ) methyl ) piperazmyl ) σumazolme A solution of l-qumazolm-2-ylpιperazme (250 mg, 1.2 mmol) and 4 -chlorobenzyl bromide (220 mg) m acetonitrile '10 mL) containing potassium carbonate (500 mg) is stπrred and heated at 60°C for 4h. After cooling the reaction is partitioned between ether and water and the organic layer extracted with 1 N HC1. The acidic extract is then basified, extracted with chloroform and the organic layer is dried and concentrated to provide the product, which may alternatively be named 1- (qumazolm-2-yl) -4- (1- [4 -chlorophenyl] methyl ) piperazme hydrochloπde, as a colorless oil (310 mg, 87%) . The oxalate salt is prepared m isopropanol. 1 H NMR (DMSO) 9.2 (s, 1H) , 7.82 (d, J = 4 Hz, 1H) , 7.72 (T, 1H) , , 7.25-7.5 ( , 6H) , 3.9 (m, 4H) , 3.75 (s, 2H) , 2.75 (m, 4H) . Example 2 1. 2-Pιperazmylguιnoxalme 2-Hydroxyqumoxalme (1.5 g) is heated m phosphorus oxychloride (10 mL) for 12 h. after which the reaction is concentrated and the residue partitioned between methylene chloride and 1 N NaOH. The resulting crude chloride is taken up m toluene (10 mL) and this solution is then added dropwise to a refluxmg solution of piperazme (5 g) m toluene (40 mL) . The resulting solution is refluxed for an additional 24 h, cooled to 0 °C for 0.5 h, filtered and concentrated. The filtrate is extracted with 10 % acetic acid and the aqueous extracts washed with ether, basified and extracted with toluene. The toluene layer is washed with water, dried and concentrated. The concentrated material, which may alternatively be named qumoxalm-2 -ylpiperazme, is placed under vacuum overnight (1.2 g, 77 %, m.p. 74-76 °C) . X H NMR (CDC1 3 ) 8.6 (s, 1H) , 7.87 (dd, J = 8 , 1 Hz, 1H) , 7.68 (dd, J = 8, 1 Hz, 1H) , 7.57 (ddd, J = 8, 7, 1 Hz, 1H) , 7.39 (ddd, J = 8, 7, 1 Hz, 1H) , 3.76 (t, J = 5 Hz, 4H) , 3.02 (t, J = 5 Hz, 4H) . 2. 1- (Qumoxalm-2-yl) -4- (1- [4- methylphenyll methyl) piperazme oxalate A solution of qumoxalm-2-ylpιperazme (325 mg, 1.53 mmol) and 4-methylbenzyl bromide (340 mg) m acetonitrile (10 mL) containing potassium carbonate (500 mg) is strirred and heated at 60°C for 4h. After cooling, the reaction is partitioned between ether and water and the organic layer extracted with 1 N HC1. The acidic extract is then basified and extracted with chloroform. The organic layer is dried and concentrated to provide the product as a colorless oil (320 mg, 66%) . The oxalate salt is prepared m isopropanol. Example 3 The following compounds are prepared essentially according to the procedures set forth above m Examples 1 and 2 : (a) 1- (qumazolm-2-yl) -4- (1- [4-chlorophenyi] - methyl) piperazme oxalate (m.p. 207-209 °C) (b) 1- (qumoxalm-2-yl) -4- (1- [4 -chlorophenyl] - methyl) piperazme oxalate (m.p. 209-212 °C) (c) 1- (3-methylqumoxalm-2-yl) -4- (1- [4 -chlorophenyl methyl) piperazme hydrobromide (m.p. 293-295 °C) (d) 1- (quιnohn-2-yl) -4- (1- [4-methylphenyl] - methyl) piperazme hydrochloπde (m.p. 278-280 °C) (e) 1- lqumolm-2-yl) -4- (1- [4- ethylphenyl] methyl) piperazme (f ) 1- (quιnolιn-2-yl) -4- (1- [4-ιsopropylphenyl] - methyl) piperazme hydrochloπde (m.p. 270-271 °C) (g) 1- (qumolm-2-yl) -4- (1- [4- tert-butylphenyl] - methyl) piperazme hydrochloπde (m.p. 285-287 °C) (h) 1- (qumolm-2-yl) -4- (1- [4 -fluorophenyl] - methyl ) piperazme (l) 1- (qumolm-2-yl) -4- (1- [4 -chlorophenyl] - methyl) piperazme hydrobromide (m.p. 268-271 °C) ( j ) 1- (qumolm-2-yl) -4- (1- [3 , 4 -dichlorophenyl] - methyl) piperazme hydrobromide (m.p. 285-287 °C) (k) 1- (qumolm-2-yl) -4- (1- [4 -trifluoromethylphenyl] - methyl) piperazme hydrobromide (m.p. 271-273 °C) (1) 1- (qumolm-2 -yl) -4 -( 1 - [4- trifluoromethoxyphenyl] - methyl) piperazme (m.p. 109-110 °C) (m) 1- (qumolm-2 -yl) -4- (1- [3, 4 -methylenedioxyphenyl] - methyl) piperazme hydrobromide (m.p. 279-280 °C) (n) 1- (4-methylqumolιn-2-yl) -4- (1- [4 -chlorophenyl] - methyl) piperazme hydrobromide (m.p. 215-217 °C) (o) 1- (4 , 6-dιmethylqumolm-2-yl) -4- (1- [4 -chlorophenyl] - methyl) piperazme hydrobromide (p) 1- (4 , 7-dιmethylqumolm-2-yl) -4- (1- [4 -chlorophenyl] - methyl) piperazme hydrobromide (m.p. 295-296 °C) (q) 1- (4 , 8-dιmethylqumolin-2-yl) -4- (1- [4 -chlorophenyl] - methyl) piperazme hydrobromide (m.p. 262-264 °C) (r) 1- (quιnol -2-yl) -4- (1- [4- chlorophenyl] ethyl) piperazme hydrobromide (m.p. 285-287 °C) (s) 1- (4-f luoroqumolm-2-yl) -4- (phenylmethyl) piperazme oxalate (m.p. 186-187°C) (t) 1- (4-f luoroqumolm-2-yl) -4- (1- [4 - fluorophenyl] - methyl) piperazme oxalate (m.p. 191-193 °C) Example 4 2 , 4 -P chloro -5 ,6,7, 8 -tetrahvdrodumazolme Dihydroxyqu azolme (10 g) is dissolved m phosphorus oxychloride (100 mL) and diethyl aniline (15 g) . The resulting dark solutuion is brought to reflux for 24 h, cooled and concentrated. The residue is taken up m chloroform, washed with ice cold IN NaOH solution, dried and concentrated. The resulting solid is recrystallized from ethyl acetate to provide the dichloro compound (9.2 g, 76 %. 2. 2 -Chloro-5 ,6,7, 8-tetrahydrodumazolme 2, 4-Dιchloro-5 , 6 , 7 , 8-tetrahydroqu azolme (4 g) is dissolved m 50 mL of methylene chloride and the resulting solution covered with 9% NH 4 OH m saturated brine. Zmc (4 g) is added and the resulting mixture gently refluxed overnight . After filtration through celite, the organic layer is washed with water, dried and concentrated. 1- (5,6,7, 8-tetrahydroqumazolm-2 -yl) -4- (1- [4- chlorophenyl] methyl) piperazme oxalate oxalate A solution of 1 g of 2 -hydroxy- 5 , 6 , 7 , 8 - tetrahydroquinazolme and 0.1 g of diethylamline m 10 mL of phosphorus oxychloride is refluxed for 2h, and subsequently cooled and concentrated. The residue is taken up in chloroform and washed with excess 3 N NaOH solution. The organic layer is dried and concentrated to provide 2 -chloro- 5 , 6 , 7 , 8- tetrahydroqumazoline (1.1 g) as an orange solid. A portion of this material (200 mg, 1.2 mmol) is mixed neat with an equivalent amount of 1- (4-chlorobenzyl) piperazme (250 mg) and the resultant mixture is heated to 150 °C under nitrogen for 30 min. Upon cooling, the resulting homogenous mixture is partitoned between chloroform and 10% NH 4 OH solution. The organic layer is dried and concentrated. The residue is then taken up in hot isopropanol 7 mL) and treated with oxalic acid (108 mg) in a minimum amount of hot isopropanol to provide the desired product, which may also be named as 2- ( (4 - (4 -chlorophenyl ) -piperazmyl) methyl) -5 , 6 , 7 , 8- tetrahydroquinazol e , oxalic acid salt, as an off-white solid (213 mg, 41 %, m.p. 210-212 °C) . Example 4 1- (5,6,7, 8-tetrahydroqumolm-2-yl) -4- (1- [4- chlorophenyl] methyl) iperazme hydrobromide A solution of 0.7 g of 2 -hydroxy-5 , 6 , 7 , 8 - tetrahydroqumolme (prepared according to the methods outlined by Meyers et al . , J. Org . Chem., 2.9: 1435-1438, 1964) and 0.1 g of diethylanil e m 7 mL of phosphorus oxychloride is refluxed for 2h, cooled and concentrated. The residue taken is up in chloroform, washed with excess 3 N NaOH solution and the organic layer dried and concentrated to provide crude 2-chloro- 5, 6, 7, 8-tetrahydro-qumolme (0.45 g) as an oil. A portion of this material (150 mg, 0.9 mmol) is mixed neat with an equivalent amount of 1- (4 -chlorobenzyl) piperazme (189 mg) and the resultant mixture heated to 150 °C under nitrogen for 20 mm. Upon cooling, the resulting homogenous mixture is triturated with isopropanol to provide the desired product, which may alternatively be named as 4- (4 -chlorophenyl) -1- (2- 5, 6, 7 , 8-tetrahydroqumolylmethyl) piperazme, hydrobromide salt, as an off-white solid (274 mg, 81 %, m.p. 281-283 °C) . --H NMR (CDC1 3 ) 7.31 (s, 4H) , 7.18 (d, J = 4 Hz, 1H) , 6.42 (d, J = 4 Hz, 1H) , 3.56 (s, 2H) , 3.52 (m, 4H) , 2.75 (m, 2H) , 2.6 (m, 6H) , 1.7-1.85 (m, 4H) . The following compound is prepared essentially according to the procedures set forth above in Examples 3 and 4 : (a) 1- (6-methoxy-4 -methylqumolm-2-yl) -4- (1- [4- chlorophenyl] methyl) piperazme hydrochloride (m.p. 250-253°C) Example 5 1- (Naphth-2 -yl) piperazme A mixture of phosphorus pentoxide (17 g) and tπethyl amme hydrochloride (16.5 g) is heated and stirred under nitrogen until melted (240 °C) . To this mixture is then added 2-ammonaphthalene (5.72 g) and diethanolamme (4.2 g) , and the temperature maintained for 0.5 h. After cooling to approx. 100 °C, the mixture is poured onto ice, neutralized with IN NaOH, and extracted with chloroform. The organic layer is washed with water, dried and concentrated. The hydrochloride salt is prepared in ethanol (8.1 g, m.p. 265-266 °C) 1- (Naphth-2-yl) -4- (1- [4 -methylphenyl] methyl - piperazme hydrochloride A solution of 1- (naphth-2 -yl ) piperazme (212 mg, 1 mmol) and 4-methylbenzyl bromide (185 mg, 1 mmol) in acetonitrile (10 mL) over potassium carbonate (500 mg) is stirred for 48 h. After partitioning between ether and water, the organic layer is extracted with IN HCl solution, and the acidic layer is then neutralized with 6 N sodium hydroxide and extracted with chloroform. The combined chloroform extracts are dried over sodium sulfate and concentrated. The resulting oil is taken up m isopropanol and treated with a saturated solution of HCl (g) m ethyl acetate to provide the product as a white crystalline solid (374 mg, 86 %) . Example 6 The following compounds are prepared essentially according to the procedures set forth above m Example 5 : (a) 1- (naphth-2-yl) -4- (1- [4- chlorophenyl] methyl) piperazme hydrochloride (m.p. 216-218 °C) (b) 1- (naphth-2-yl) -4- (1- [4- methylphenyl] methyl) piperazme hydrobromide 'm.p. 222-223 °C) (c) 1- (naphth-2-yl) -4- (1- [4- fluorophenyl] methyl) piperazme hydrobromide (m.p. 244-246 °C) (d) 1- (naphth-2-yl) -4- (1- [3- fluorophenyl] methyl) piperazme hydrobromide m.p. 253-255 °C) (e) 1- (naphth-2-yl) -4- (1- [2- fluorophenyl] methyl) piperazme hydrobromide (m.p. 239-240 °C) Example 7 Assay for D and D Receptor Binding Activity The pharmaceutical utility of compounds of this invention is indicated by the assays for dopamme receptor subtype affinity described below. Pellets of COS cells containing recombmantly produced D2 or D4 receptors from African Green monkey are used for the assays. The sample is homogenized m 100 volumes (w/vol) of 0.05 M Tπs HCl buffer at 4° C and pH /.4. The sample is then centπfuged at 30,000 x g and resuspended and rehomogenized. The sample is again centπfuged as described above and the final tissue sample is frozen until use. The tissue is resuspended 1:20 (wt/vol) m 0.05 M Tris HCl buffer containing 100 mM NaCl. Incubations are carried out at 48°C and contain 0.4 ml of tissue sample, 0.5 nM 3 H-YM 09151-2 (Nemonapride , cιs-5-Chloro- 2-methoxy-4- (methylammo) -N- (2-methyl-2- (phenylmethyl) -3- pyrrolid yl) benzamide) and the compound of interest in a total incubation of 1.0 ml. Nonspecific binding is defined as that binding found in the presence of 1 mM spiperone; without further additions, nonspecific binding is less than 20% of total binding. Binding characteristics for examples of compounds encompassed within Formula I for the D2 and D4 receptor subtypes are shown in Table 2 for rat striatal homogenates . TABLE 2 Binding of compounds of the invention to D 4 and D 2 receptors cloned from African Green monkey. Compound Number D 4 K (nM) D 2 K x (nM) 2 >4000 3 11 >4000 6 9 >4000 7 7 1927 Compound numbers m Table 2 relate to compounds shown m Table 1. The binding characteristics of compounds of Formula I for the D 4 receptor, expressed m nM, generally range from about 0.5 nanomolar (nM) to about 25 nanomolar (nM) . These compounds typically have binding constants for the D 2 receptor of from about 200 nM to more than 1000 nM. Thus, the compounds of the invention are generally at least about 10 time more selective for the D 4 receptor than the D 2 receptor. Preferably, these compounds are at least 20, and more preferably at least 25-50, times more selective for the D„ receptor than the D 2 receptor. Most preferably, these compounds are at least 100 times more selective for the D 4 receptor than the D 2 receptor. Example 8 A compound described Arch. Med. Res., 2 . 5: 435-440 (Terron et al . , 1994), 1- (qumolm-2-yl) -4-benzylpιperazme (Comparative Compound B) , was evaluated m the assays described above. Comparative Compound B demonstrated relatively weak interaction with the D 4 receptor subtype (IC 50 = 194 nM) . A compound described m Toxicol. Appl . Pharmacol., 2 : 257- 267 (Schmidt and Martin, 1965) , l-naphth-2-yl-4- benzylpiperaz e (Comparative Compound A) , was evaluated m the assays described above. Comparative Compound A demonstrated relatively weak interaction with the D 4 receptor subtype (IC 50 = 33 nM) . The invention and the manner and process of making and using it, are now described m such full, clear, concise and exact terms as to enable any person skilled m the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

Claims: What is claimed is: 1. A compounds of the formula or pharmaceutically acceptable addition salts thereof, wherem: X, Y and Z are the same or different and represent CR C or nitrogen,* R c represents hydrogen, halogen or C ^ -C, alkyl; Rx and R 2 independently represent hydrogen, halogen, hydroxy, Cχ-C 6 alkyl, trifiuoromethyl, trifluoromethoxy or S0 2 NH 2 , provided that, when Y and Z represent CH, and R 3 and R 4 are both hydrogen, R x and R 2 are not hydrogen simultaneously; or R x and R 2 together represent a C -C 2 alkylene dioxy group or a C 1 -C 3 alkylene oxy group; R 3 and R 4 are the same or different and represent hydrogen, halogen, Cχ-C 6 alkyl, Cχ-C 4 alkoxy, alkylthio, hydroxy, ammo, mono or dialkyl ammo where each alkyl is C ^ -C 6 alkyl, cyano or trifiuoromethyl; A represents C ^ -C. alkylene; and R 5 , R 6 , and R 7 independently represent hydrogen or Cχ-C 6 alkyl. 2. A compound according to claim 1, wherem at least one of R γ and R 2 is halogen, alkyl, trifiuoromethyl, trifluoromethoxy, or R λ and R 2 together represent 3,4- methylenedioxy . 3. A compound according to claim 1, wherem at least one of R x and R 2 is chloro, fluoro, methyl, ethyl, butyl, isopropyl, n-propyl, trifiuoromethyl, trifluoromethoxy, or R, and R 2 together represent 3 , 4 -methylenedioxy. 4. A compound according to claim 1, wherem R 3 and R 4 are hydrogen, A is methylene, R 2 is hydrogen and R,_ is methyl or chloro. 5. A compound of the formula: or the pharmaceutically acceptable addition salts thereof, wherem : R c is hyrogen, halogen, or C-C 8 alkyl; Rx and R 2 independently represent hydrogen, halogen, hydroxy, Cχ-C 6 alkyl, trifiuoromethyl, trifluoromethoxy or S0 2 NH 2 , provided that, when R_, R 3 and R „ are all hydrogen, R and R 2 are not hydrogen simultaneously; or R_ and R 2 together represent a C 1 -C 2 alkylene dioxy group or a alkylene oxy group; R 3 and R 4 are the same or different and represent hydrogen, halogen, Cχ-C 6 alkyl, Cχ-C 4 alkoxy, alkylthio, hydroxy, ammo, mono or dialkyl ammo where each alkyl is Cχ-C 6 alkyl, cyano or trifiuoromethyl; A represents C 1 -C 4 alkylene; and R 5 , R 6 , and R 7 are the same or different and represent hydrogen or Cχ-C 6 alkyl . 6. A compound according to claim 5, wherem represents 4-alkylqumolmyl , 4,6- dialkylqumolmyl, 4 , 7-dιalkylqumolmyl , 4,8- dialkylqu olmyl , 4-haloqumolmyl , or 4 -alkyl -6- alkoxyqumol yl . 7. A compound of the formula: or pharmaceutically acceptable addition salts thereof, wherein: Rx and R 2 independently represent hydrogen, halogen, hydroxy, Cχ-C 6 alkyl, trifiuoromethyl, trifluoromethoxy or S0 2 NH 2 ; or R x and R 2 together represent a C.,-C 2 alKylene dioxy group or a C ι ~C 3 alkylene oxy group; R 3 and R 4 are the same or different and represent hydrogen, halogen, C -C 6 alkyl, C -C 4 alkoxy, alkylthio, hydroxy, ammo, mono or dialkyl ammo where each alkyl is Cχ-C 6 alkyl, cyano or trifiuoromethyl; A represents C 1 -C li alkylene; and R 5 , R 6 , and R 7 independently represent hydrogen or Cχ-C 6 alkyl. 8. A compound of the formula: or pharmaceutically acceptable addition salts thereof, wherem: Rx and R 2 independently represent hydrogen, halogen, hydroxy, Cχ-C 6 alkyl, trifiuoromethyl, trifluoromethoxy or S0 2 NH 2 ,* or R x and R 2 together represent a C^C j alkylene dioxy group or a C ι "C 3 alkylene oxy group; R 3 and R 4 are the same or different and represent hydrogen, halogen, Cχ-C 6 alkyl, Cχ-C 4 alkoxy, alkylthio, hydroxy, am o, mono or dialkyl ammo where each alkyl is Cχ-C 6 alkyl, cyano or trifiuoromethyl; R 5 , R 6 , and R 7 are the same or different and represent hydrogen or Cχ-C 6 alkyl . A compound of the formula: or pharmaceutically acceptable addition salts thereof, wherein: R c is hydrogen, halogen or alkyl; Rx and R 2 independently represent hydrogen, halogen, hydroxy, Cχ-C 6 alkyl, trifiuoromethyl, trifluoromethoxy or S0 2 NH 2 , * or R,_ and R 2 together represent a C 1 -C 2 alkylene dioxy group or a C-C-, alkylene oxy group; R 3 and R 4 independently represent hydrogen, halogen, Cχ-C 6 alkyl, Cχ-C 4 alkoxy, alkylthio, hydroxy, amino, mono or dialkyl amino, cyano or trifiuoromethyl; R 5 , R 6 , and R 7 independently represent hydrogen or Cχ-C 3 alkyl. 10. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [4 -methylphenyl] methyl) piperazine . 11. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [4 -ethylphenyl] methyl) piperazine . 12. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [4- tert-butylphenyl] methyl) piperazme . 13. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [4-fluorophenyl] methyl) piperaz e . 14. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperaz e . 15. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [3 , 4 -dichlorophenyl] methyl) piperaz e . 16. A compound according to claim 1, which s 1- (qumolm-2-yl) -4- (1- [4- tπfluoromethylphenyl] methyl) piperazme . 17. A compound according to claim 1, which is 1- (qumolιn-2-yl) -4- (1- [4- trifluoromethoxyphenyl] methyl) piperazme . 18. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [3,4- methylenedioxyphenyl] methyl) piperazme . 19. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [4 -sulfonamidophenyl] methyl) piperazme . 20. A compound according to claim 1, which is 1- (5, 6,7,8- tetrahydroqumolm-2-yl) -4- (1- [4- chlorophenyl] methyl) piperazme . 21. A compound according to claim 1, which is 1- (4- methylqumolm-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperaz e . 22. A compound according to claim 1, which is l-(4,6- dιmethylqumolιn-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperazine. 23. A compound according to claim 1, which is l-(4,7- dιmethylqumolm-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperaz e . 24. A compound according to claim 1, which is l-(4,8- dιmethylquιnolm-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperazine . 25. A compound according to claim 1, which is 1- (6- methoxy-4-methylqumolm-2-yl) -4- (1- [4- chlorophenyl] methyl ) piperazme . 26. A compound according to claim 1, which is 1- (qumolm-2-yl) -4- (1- [4 -chlorophenyl] ethyl) piperaz e . 27. A compound according to claim 1, which is l-(4- fluoroqumolm-2-yl) -4- (1 -phenylmethyl) piperaz e . 28. A compound according to claim 1, which s l-(4- fluoroqumolm-2-yl) -4- (1- [4 - fluorophenyl] methyl ) piperaz e . 29. A compound according to claim 1, which is 1- (qumoxalm-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperazme . 30. A compound according to claim 1, which is l-(3- methylqumoxalm-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperazme . 31. A compound according to claim 1, which is 1- (qumazolm-2-yl) -4- (1- [4 -chlorophenyl] methyl) piperazme . 32. A compound according to claim 1, which is l-(5, 6,7,8- tetrahydroquιnazolm-2-yl) -4- (1- [4- chlorophenyl ] methyl ) piperazme . 33. A compound according to claim 1, which is 1- (naphth- 2-yl) -4- (1- [4 -chlorophenyl] methyl) piperazme . 34. A compound according to claim 1, which is 1- (naphth- 2-yl) -4- (1- [4 -methylphenyl] methyl) piperazme . 35. A compound according to claim 1, which is 1- (naphth- 2-yl) -4- (1- [4-fluorophenyl] methyl) piperazme . 36. A compound according to claim 1, which is l-(naphth- 2-yl) -4- (1- [3 -fluorophenyl] methyl) piperazme . 37. A compound according to claim 1, which is 1- (naphth- 2-yl) -4- (1- [2-fluorophenyl] methyl) piperazme . 38. A compound of the formula where X, Y and Z are the same or different and represent CR C or nitrogen; R c represents hydrogen, halogen or alkyl; R 3 and R 4 are the same or different and represent hydrogen, halogen, Cχ-C 6 alkyl, Cχ-C 4 alkoxy, alkylthio, hydroxy, amino, mono or dialkyl ammo where each alkyl is Cχ-C 6 alkyl, cyano or trifiuoromethyl; A represents C x -C 4 alkylene; and R 6 and R 7 independently represent hydrogen or Cχ-C 6 alkyl. 39. A compound according to claim 38, wherem X and Y are nitrogen and Z is CH. 40. A compound according to claim 38, wherem X, Y, and Z are CH. 41. A compound according to claim 38, wherem X and Z are nitrogen and Y is CH.

Inventors: GANGULY ASHIT, GREENLEE WILLIAM, WASLEY JAN W F, GANGULY, ASHIT, GREENLEE, WILLIAM, WASLEY, JAN, W., F.
Applicants: GANGULY ASHIT, GREENLEE WILLIAM, NEUROGEN CORP, SCHERING CORP, WASLEY JAN W F, GANGULY, ASHIT, GREENLEE, WILLIAM, NEUROGEN CORPORATION, SCHERING CORPORATION, WASLEY, JAN, W., F.
Application year: 1998
Main classification: C07D403
IPC codes: C07D215, C07D239, C07D241, C07D295